Available Technology

Greater than 20% of traumatic wound closure attempts fail due to the immuno-molecular status of the healing wound tissue. 

A technology related to novel methods of using small molecule compounds for treating myeloid neoplasms and solid tumor is available for licensing or collaboratively developing from HJF.

Researchers at HJF, Inova Fairfax Hospital (IFH), and the Peter MacCallum Cancer Centre (PMCC) have identified orthogonal protein and transcript-based biomarkers correlating with Homologous...

Technology is related to using antibodies, antibody-drug conjugates, and chimeric antigen receptor (CAR) transduced immune cells that selectively targets Ly6 family of proteins overexpressed in cancer...

HJF researchers develop novel vaccine strategy against HIV-1

Surgical simulator that allows hands-on surgical training using techniques of vascular shunt and anastomosis to save life and limb.